Clinical Research Directory

Anemia in Systemic Lupus Erythematosus Specially Refractory Type

Sponsor: Assiut University

Summary

Systemic lupus erythroematosis (SLE) is a systemic autoimmune disease with multisystemic involvement. The condition has several phenotypes, with varying clinical presentations from mild mucocutaneous manifestations to multiorgan and severe central nervous system involvement. Several immunopathogenic pathways play a role in the development of SLE. Despite recent advances in technology and understanding of the pathological basis and risk factors for SLE, the exact pathogenesis is still not well known. Diagnosis of SLE can be challenging, and while several classification criteria have been posed, their utility in the clinical setting is still a matter of debate. Management of SLE is dictated by organ system involvement. Despite several agents shown to be efficacious in treating SLE, the disease still poses significant morbidity and mortality risks in patients\[1\]. Haematological abnormalities are common in systemic lupus erythroematosis. Anemia is found in about 50% of patients.

Official title: What is Behind Anemia in Systemic Lupus Erythematosus With Special Reference to Referactory Anemia

Key Details

Conditions

Interventions